Standard treatment options in patients who have advanced melanoma with rapidly accelerated fibrosarcoma (RAF) B-type proto-oncogene (BRAF) V600 mutations include immune checkpoint inhibition described previously as well as combinations of targeted therapies with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors: dabrafenib plus trametinib, encorafenib plus binimetinib, and vemurafenib plus cobimetinib 1. This evidence concerns the gene MAP2K7 and melanoma.